当前位置: X-MOL 学术J. Recept. Signal Transduct. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The role of programed death-ligand 1 in renal diseases
Journal of Receptors and Signal Transduction ( IF 2.8 ) Pub Date : 2020-03-02 , DOI: 10.1080/10799893.2020.1734820
Yi Wei 1 , Zongpei Jiang 1
Affiliation  

Abstract Programed death-ligand 1 (PD-L1, B7-H1, CD274) is a coinhibitory molecule that plays a vital role in the pathogenesis of both neoplastic and nonneoplastic diseases. However, the role of PD-L1 in primary and secondary renal diseases remains to be clarified. Previous studies have shown that both intracellular and intercellular PD-L1 participate in renal diseases via complex mechanisms. PD-L1 plays a dual role in lupus nephritis and has a protective effect in renal ischemia reperfusion injury and nephrotoxic nephritis but not in proliferative immune complex glomerulonephritis. PD-L1 supplementation, anti-PD-L1 antibodies, and D-peptide antagonists have promising application prospects in the treatment of renal diseases. In this review, we summarize the available data published on PD-L1 in renal diseases for the first time.

中文翻译:

程序性死亡配体1在肾脏疾病中的作用

摘要 程序性死亡配体 1(PD-L1、B7-H1、CD274)是一种共抑制分子,在肿瘤和非肿瘤疾病的发病机制中都起着至关重要的作用。然而,PD-L1 在原发性和继发性肾脏疾病中的作用仍有待阐明。先前的研究表明,细胞内和细胞间 PD-L1 均通过复杂的机制参与肾脏疾病。PD-L1在狼疮性肾炎中发挥双重作用,对肾缺血再灌注损伤和肾毒性肾炎有保护作用,但对增殖性免疫复合物肾小球肾炎无保护作用。PD-L1 补充剂、抗 PD-L1 抗体和 D-肽拮抗剂在肾脏疾病治疗中具有广阔的应用前景。在这篇综述中,我们首次总结了关于 PD-L1 在肾脏疾病中发表的可用数据。
更新日期:2020-03-02
down
wechat
bug